Table D14. Medication adherence outcomes 6

| Author, YearTrial name  | Medication Adherence Outcome 6 | Description of Timing of Measurement of Adherence Outcome 6 | Data Source  | N | Results |
| --- | --- | --- | --- | --- | --- |
| Hoffman et al., 200318NA | Persistency (defined as thetime span a patient continued taking the antidepressantprescription during the study. If the date of thelast prescription filled plus the days’ supply was ≤10days from the end of the study, the patient was consideredto be persistent) | Measured for previous 30 days, at 2, 3, 4, 5, and 6 months | PRD | G1: 4889G2: 4665 | **At 2 months**:G1: 45.9G2: 44.3**At 3 months:**G1: 36.8G2: 35.3**At 4 months:**G1: 30.2G2: 28.9**At 5 months**:G1: 28.8G2: 27.3**At 6 months:**G1: 24.9G2: 23.495%Cis & p: NR**From 1-90 days**:Mean percent (SD): G1: 36.8 (24.3)G2: 35.3 (12.4)Chi-square: 0.12795% CI, NRp: NR**From 1-180 days**:Mean percent (SD): G1: 24.9 (51.9)G2: 23.3 (51.9)Chi-square: 0.06795% CI, NRp: NR |
| Murray et al., 200736NA | Self-reported adherence from questionnaire at baseline and 9 month to compute a composite score of self-reported adherence | Measured at 1 month prior to intervention (baseline) and at month 9 | Self-report | G1: NRG2: NR | G1: 1.0G2: 0.895% CI, NR p: 0.48 |
| Pyne et al., 201141HIV Translating Initiatives for Depression Into Effective Solutions (HITIDES) | antidepressant prescription rates (of providers) at 12 months | Not clear whether self-report or other method. 3 measurements taken: baseline, 6-month and 12-months.  | Other  | G1: 65/105 (61.9)G2: 69/110 (62.7) | G1: 65/105 (61.9)G2: 69/110 (62.7),OR: 0.93 (0.49-1.78); adjusted OR: 0.93 (0.49-1.78)Adjusted p: 0.93 |
| Stacy et al., 200956NA | 6 month point prevalence persistency: subject being in possession of a statin at the end of the 180-day observation period (For those with continuous persistance + MPR=>80%) | 6 months after baseline; 1 time; N/A | PRD | Overall N:NRSG1: NRSG2: NR | SG1: 25.9%SG2: 3.3%95% CI, NRp: <0.05 |
| Vivian et al., 200258NA | % that received refills for antihypertensive agents within 2 weeks of the next scheduled refill date | NR | PRD | G1: 26G2: 27 | G1: 85%G2: 93%95% CI, NRp: >0.42 |
| Wilson et al., 201065Better Outcomes of Asthma Treatment (BOAT) | Medication acquisition at Year 1 and Year 2 -for long-acting beta agonists (LABA) Fill/reﬁll adherence was measured using a continuousmedication acquisition (CMA) index for each year, calculated as the total days’ supply acquired in a given year divided by 365 days | Measured as aggregate for year; at Year-1 follow-up and Year 2 follow-up | PRD | N for Year 1:G1: 40G2: 44G3: 52N for Year 2: G1:112G2: 108G3:59 | Group differencesYEAR 1:G1-G3: 0.1195% CI, 0.02 to 0.20G1-G2: 0.0995% CI, 0.02 to 0.17G2-G3: 0.01 95% CI, -0.08 to 0.11YEAR 2: G1-G3: 0.1195% CI, 0.01 to 0.20G1:G2: 0.0995% CI, 0.01 to 0.18G2-G3: 0.0195% CI, -0.08 to 0.11 |